VDX-111 targets proliferative pathways in canine cancer cell lines

Area of Science:

• Oncology
• Pharmacology
• Veterinary Medicine

Background:

• Vitamin D derivatives are being explored for anticancer properties.
• VDX-111 (AMPI-109) is a novel vitamin D derivative with demonstrated anticancer activity.
• Canine cancer research provides a valuable model for comparative oncology.

Purpose of the Study:

• To evaluate the efficacy of VDX-111 against a diverse panel of canine cancer cell lines.
• To identify potential predictive markers for VDX-111 sensitivity.
• To investigate the molecular mechanisms underlying VDX-111's anticancer effects.

Main Methods:

• Testing VDX-111 on 30 characterized canine cancer cell lines.
• Assessing growth inhibition, cell death, and migration inhibition.
• Correlating drug sensitivity with gene expression in cell signaling pathways (MAPK, PI3K-AKT).

Main Results:

• VDX-111 demonstrated variable efficacy across different canine cancer types.
• Sensitivity to VDX-111 was significantly correlated with the expression of genes in the MAPK and PI3K-AKT pathways.
• Inhibition of these signaling pathways was confirmed as a likely mechanism of action.

Conclusions:

• A subset of canine tumors may be sensitive to VDX-111 treatment.
• Gene expression in MAPK and PI3K-AKT pathways may serve as predictive biomarkers for VDX-111 sensitivity.
• VDX-111 shows promise for future clinical trials in canine oncology.